1997
A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group.
Tuttleman M, Pillemer S, Tilley B, Fowler S, Buckley L, Alarcón G, Trentham D, Neuner R, Clegg D, Leisen J, Heyse S. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. The Journal Of Rheumatology 1997, 24: 1910-5. PMID: 9330931.Peer-Reviewed Original ResearchConceptsPatient global assessmentSF-36Rheumatoid arthritisM-HAQOutcome measuresClinical trialsGlobal assessmentShort Form Health SurveyFunctional health status measuresJoint swelling scoreRA clinical trialsRA outcome measuresHealth Assessment QuestionnaireHealth status instrumentsSF-36 scalesRheumatoid arthritis trialsHealth status measuresMultitrait scaling analysisCross-sectional assessmentCross-sectional analysisMIRA trialStudy patientsRA populationScore correlationsPain itemsRadiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial.
Bluhm G, Sharp J, Tilley B, Alarcon G, Cooper S, Pillemer S, Clegg D, Heyse S, Trentham D, Neuner R, Kaplan D, Leisen J, Buckley L, Duncan H, Tuttleman M, Li S, Fowler S. Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. The Journal Of Rheumatology 1997, 24: 1295-302. PMID: 9228128.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Bacterial AgentsArthritis, RheumatoidArthroscopyFemaleHumansMaleMiddle AgedMinocyclinePlacebosRadiographyTreatment OutcomeConceptsJoint space narrowingRheumatoid arthritis trialsDisease progressionArthritis trialsSpace narrowingPercentage of patientsSignificant differencesReported clinical resultsErosive jointsOral minocyclinePlacebo groupErosive diseaseFinal visitRadiographic progressionPlacebo treatmentTreat analysisRadiographic resultsFuture trialsClinical centersClinical resultsPosteroanterior filmsRadiographic changesTreatment benefitProgression rateWeek trial
1995
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Tilley B, Alarcón G, Heyse S, Trentham D, Neuner R, Kaplan D, Clegg D, Leisen J, Buckley L, Cooper S, Duncan H, Pillemer S, Tuttleman M, Fowler S. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Annals Of Internal Medicine 1995, 122: 81-9. PMID: 7993000, DOI: 10.7326/0003-4819-122-2-199501150-00001.Peer-Reviewed Original ResearchConceptsIgM rheumatoid factor levelsErythrocyte sedimentation rateRheumatoid factor levelsRheumatoid arthritisMinocycline groupGlobal assessmentPlacebo groupMore patientsPlatelet countModified Health Assessment QuestionnaireFactor levelsEfficacy of minocyclineEvaluator's global assessmentWeek 48 visitActive rheumatoid arthritisHealth Assessment QuestionnairePatient global assessmentPlacebo-controlled trialModerate rheumatoid arthritisDisease-modifying drugsMechanism of actionJoint tendernessMorning stiffnessStudy medicationDisease activity